vtx-2337 and Neoplasms

vtx-2337 has been researched along with Neoplasms* in 4 studies

Trials

1 trial(s) available for vtx-2337 and Neoplasms

ArticleYear
Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337).
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Dec-15, Volume: 21, Issue:24

    Immunotherapy as a treatment for cancer holds the promise of complete and durable tumor remission, yet the immunosuppressive environment created by many tumors, advanced patient age, and previous treatments with cytotoxic agents may limit the approach. The activity of motolimod (VTX-2337), a potent and selective Toll-like receptor 8 (TLR8) agonist, was therefore assessed in the context of advanced, late-stage cancer patients.. The repertoire of mediators induced from human peripheral blood mononuclear cells in response to motolimod was characterized. Translational studies in cynomolgus monkeys elucidated the activity of motolimod on an intact immune system, identified biomarkers of TLR8 activation, and defined the relationship between the pharmacokinetic and pharmacodynamic (PK/PD) response. The PK/PD relationship for motolimod in cancer patients was assessed, compared with preclinical findings, and contrasted with activity in healthy volunteers.. In late-stage cancer patients, plasma levels of multiple biomarkers, including IL6, G-CSF, MCP-1, and MIP1-β, increased with increasing motolimod dose. The magnitude and breadth of the biomarker response closely aligned with the response seen in preclinical studies, demonstrating that advanced cancer patients remained responsive to TLR8 activation. In addition, the PK/PD response in cancer patients closely aligned with the activity of motolimod seen in healthy volunteers.. Late-stage cancer patients are highly sensitive to TLR8 activation by motolimod. Tumor burden, advanced age, and prior treatment history with cytotoxic agents did not moderate or modify the response predicted by nonclinical studies and confirmed in healthy volunteers. Clin Cancer Res; 21(24); 5445-52. ©2015 AACR.

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Benzazepines; Case-Control Studies; Combined Modality Therapy; Cytokines; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Immunomodulation; Immunotherapy; Leukocyte Count; Leukocytes; Macaca fascicularis; Male; Middle Aged; Neoplasm Staging; Neoplasms; Signal Transduction; Toll-Like Receptor 8; Treatment Outcome

2015

Other Studies

3 other study(ies) available for vtx-2337 and Neoplasms

ArticleYear
DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy.
    Journal of materials chemistry. B, 2021, 09-22, Volume: 9, Issue:36

    Immunosuppressed tumor microenvironment (TME) is a major cause of the low response rate in solid tumor patients during PD-1/PD-L1 checkpoint blockade therapy. In this study, a series of small molecule nanomedicines with a 100% drug loading rate were prepared

    Topics: Animals; Antineoplastic Agents; B7-H1 Antigen; Benzazepines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Docetaxel; Drug Synergism; Female; Immunologic Factors; Immunotherapy; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Small Molecule Libraries; Transplantation, Homologous; Tumor Microenvironment

2021
The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent.
    Scientific reports, 2021, 01-15, Volume: 11, Issue:1

    The Toll-like receptor 8 (TLR8) agonist VTX-2337 (motolimod) is an anti-cancer immunotherapeutic agent that is believed to augment natural killer (NK) and dendritic cell (DC) activity. The goal of this work is to examine the role of TLR8 expression/activity in head and neck squamous cell carcinoma (HNSCC) to facilitate the prediction of responders to VTX-2337-based therapy. The prognostic role of TLR8 expression in HNSCC patients was assessed by TCGA and tissue microarray analyses. The anti-tumor effect of VTX-2337 was determined in SCCVII/C3H, mEERL/C57Bl/6 and TUBO-human EGFR/BALB/c syngeneic mouse models. The effect of combined VTX-2337 and cetuximab treatment on tumor growth, survival and immune cell recruitment was assessed. TLR8 expression was associated with CD8+ T cell infiltration and favorable survival outcomes. VTX-2337 delayed tumor growth in all 3 syngeneic mouse models and significantly increased the survival of cetuximab-treated mice. The anti-tumor effects of VTX-2337+ cetuximab were accompanied by increased splenic lymphoid DCs and IFNγ+ CD4+ and tumor-specific CD8+ T cells. Depletion of CD4+ T cells, CD8+ T cells and NK cells were all able to abolish the anti-tumor effect of VTX-2337+ cetuximab. Altogether, VTX-2337 remains promising as an adjuvant for cetuximab-based therapy however patients with high TLR8 expression may be more likely to derive benefit from this drug combination compared to patients with low TLR8 expression.

    Topics: Animals; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Benzazepines; Biomarkers, Pharmacological; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cetuximab; Cytokines; Databases, Genetic; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Killer Cells, Natural; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Neoplasms; Squamous Cell Carcinoma of Head and Neck; T-Lymphocytes; Toll-Like Receptor 8

2021
Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity.
    PloS one, 2016, Volume: 11, Issue:2

    VTX-2337 (USAN: motolimod) is a selective toll-like receptor 8 (TLR8) agonist, which is in clinical development as an immunotherapy for multiple oncology indications, including squamous cell carcinoma of the head and neck (SCCHN). Activation of TLR8 enhances natural killer cell activation, increases antibody-dependent cell-mediated cytotoxicity, and induces Th1 polarizing cytokines. Here, we show that VTX-2337 stimulates the release of mature IL-1β and IL-18 from monocytic cells through coordinated actions on both TLR8 and the NOD-like receptor pyrin domain containing 3 (NLRP3) inflammasome complex. In vitro, VTX-2337 primed monocytic cells to produce pro-IL-1β, pro-IL-18, and caspase-1, and also activated the NLRP3 inflammasome, thereby mediating the release of mature IL-1β family cytokines. Inhibition of caspase-1 blocked VTX-2337-mediated NLRP3 inflammasome activation, but had little impact on production of other TLR8-induced mediators such as TNFα. IL-18 activated natural killer cells and complemented other stimulatory pathways, including FcγRIII and NKG2D, resulting in IFNγ production and expression of CD107a. NLRP3 activation in vivo was confirmed by a dose-related increase in plasma IL-1β and IL-18 levels in cynomolgus monkeys administered VTX-2337. These results are highly relevant to clinical studies of combination VTX-2337/cetuximab treatment. Cetuximab, a clinically approved, epidermal growth factor receptor-specific monoclonal antibody, activates NK cells through interactions with FcγRIII and facilitates ADCC of tumor cells. Our preliminary findings from a Phase I open-label, dose-escalation, trial that enrolled 13 patients with recurrent or metastatic SCCHN show that patient NK cells become more responsive to stimulation by NKG2D or FcγRIII following VTX-2337 treatment. Together, these results indicate that TLR8 stimulation and inflammasome activation by VTX-2337 can complement FcγRIII engagement and may augment clinical responses in SCCHN patients treated with cetuximab.. ClinicalTrials.gov NCT01334177.

    Topics: Animals; Benzazepines; Carrier Proteins; Caspase 1; Cell Degranulation; Cell Line, Tumor; Cytotoxicity, Immunologic; Disease Models, Animal; Female; Humans; Inflammasomes; Interleukin-18; Interleukin-1beta; K562 Cells; Killer Cells, Natural; Leukocytes, Mononuclear; Lymphocyte Activation; Macaca fascicularis; Male; Neoplasms; NLR Family, Pyrin Domain-Containing 3 Protein; Receptors, IgG; Toll-Like Receptor 8

2016